compani
wrap beat/rais lower po group
de-rat lower estimate matur product
remain neutral potenti headwind key product
follow slight beat revenu beat/rais ep forecast higher
ep vs prior higher top line lower tax rate partial off-set
higher sg support new product launch convers moder po
prior mainli driven lower pe multipl
us major pharma group de-rat lesser extent lower
top-lin forecast due lower humalog forecast base result taltz
psoriasi verzenio cancer post strong sale may see tailwind
label expans first-in-class surviv benefit vs competitor respect
increas estim product beyond given cautiou
potenti step-up competit pressur skyrizi psoriasi safeti profil
verzenio remain neutral given potenti headwind key product
limit catalyst potenti upsid lli premium multipl
take-away confer call
redesign neutral/posit implement diabet portfolio primari part
exposur neg impact immunolog oncolog vs increas
medicaid rebat cap headwind exposur due insulin exposur
lastli cap price increas meaning impact given price power
alreadi moder lli portfolio us trulic disconnect net sale
script growth driven higher rebat rate maintain open payer access partial
off-set list price increas follow donut hole expans mix shift taltz
meaning chang vs net price skyrizi mostli take share
biolog stelara cosentyx verzenio management frame overal surviv os
benefit key differenti vs molecul given
first-in-class data support use verzenio chemo-spar option difficult-to-
treat patient popul progress initi endocrin therapi
competitor note ibranc os data matur time analysi vs
kisqali demonstr os benefit set continu focu bolts-on
deal oppos larg scale
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
compani juli
compani
biopharmaceut compani
diversifi therapeut focu product
focus treat diseas condit
diabet cancer immunolog central nervou
system disord deep pipelin drug
therapeut focu mirror commerci
portfolio found
incorpor indiana top sell
product includ humalog sale
ciali alimta forteo
one highest ep growth name among
us major pharma new product launch
cost cut measur expect drive
neutral believ stock beat
street estim achiev multipl expans
given competit payer headwind
compani diabet categori
risk new brand launch disappoint consensu
verzenio taltz set tough target
compani
price object po base blend averag discount
cash flow dcf multipl appli ep dcf assum
wacc termin growth price-to-earnings multipl base regress analysi
histor us major pharma peer forward month price-to-earnings multipl three-
upsid risk po better-than-anticip margin expans on-going
cost-cut program verzenio show meaning clinic differenti
result signific uptak
downsid risk po slower growth trulic rapid biosimilar eros
humalog franchis slower growth new product launch
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
compani juli
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
compani juli
